Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Misses Estimates By $0.54 EPS

Emergent Biosolutions (NYSE:EBS) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54), FiscalAI reports. The business had revenue of $148.70 million during the quarter, compared to analysts’ expectations of $217.50 million. Emergent Biosolutions had a return on equity of 15.62% and a net margin of 7.08%.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Strong 2025 financial recovery: Adjusted EBITDA of $205M (up 12% YoY), adjusted EPS of $1.53 (versus a loss in 2024), gross margin +900 bps, and operating expenses down $140M, demonstrating material margin expansion and profitability improvement.
• 2026 guidance is more conservative: Revenue guided to $720M–$760M and adjusted EBITDA to $135M–$155M (reflecting the absence of a one‑time $60M international order in 2025), and the company still expects a GAAP net loss for 2026.
• International MCM momentum and major contract wins: International sales now ~34% of MCM revenue with new multi‑year Canadian agreements (~CAD 140M) and deliveries to 20+ countries, positioning international growth as a key driver.
• NARCAN franchise updates — product and market positioning: The company maintained market leadership, won FDA approval for 6‑ and 24‑count multi‑packs and is launching a consumer carrying case, but Q4 commercial demand was temporarily softened by the U.S. government shutdown.
• Deleveraging and capital returns: Ended 2025 with $205M cash ($305M liquidity), repaid $110M gross debt (including a $100M term‑loan prepayment), repurchased shares and bonds, and approved a new $50M buyback authorization.

Emergent Biosolutions Price Performance

EBS opened at $8.19 on Friday. The stock’s 50 day moving average price is $11.68 and its 200-day moving average price is $10.40. Emergent Biosolutions has a 52-week low of $4.02 and a 52-week high of $14.06. The stock has a market capitalization of $429.98 million, a PE ratio of 9.75 and a beta of 2.35. The company has a debt-to-equity ratio of 1.14, a quick ratio of 3.15 and a current ratio of 5.76.

Insiders Place Their Bets

In other Emergent Biosolutions news, Director Ronald Richard sold 21,984 shares of the company’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the transaction, the director directly owned 98,417 shares in the company, valued at approximately $1,178,051.49. This represents a 18.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Trust Advisors LP purchased a new stake in shares of Emergent Biosolutions in the 4th quarter worth approximately $179,000. Zacks Investment Management purchased a new stake in shares of Emergent Biosolutions in the fourth quarter worth $141,000. Vise Technologies Inc. bought a new position in shares of Emergent Biosolutions during the fourth quarter valued at $131,000. Abel Hall LLC bought a new position in Emergent Biosolutions in the 4th quarter worth about $129,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Emergent Biosolutions during the 2nd quarter valued at about $124,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently commented on EBS shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Emergent Biosolutions in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Finally, Wall Street Zen downgraded Emergent Biosolutions from a “strong-buy” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $15.00.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Won multiyear Canadian contracts worth up to ~CAD 140 million, including >CAD 35M in orders expected in 2026, which adds near-term funded backlog and visibility for future revenue. Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada
• Positive Sentiment: Board authorized a new $50 million stock repurchase program (replacing the prior authorization); buybacks can support the share price and signal confidence from management. Emergent BioSolutions Announces New $50 Million Stock Repurchase Program
• Positive Sentiment: Company highlights a return to profitability and ongoing turnaround progress, which could improve investor sentiment if execution continues. Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
• Neutral Sentiment: Full Q4 prepared remarks, slide deck and presentation materials were filed — useful for digging into segment trends, contract timing and margin details but not a near-term catalyst by itself. Earnings Call Prepared Remarks Transcript Q4 Results – Earnings Call Presentation
• Neutral Sentiment: Local coverage and snapshots summarize the quarter and management commentary; useful background for investors reviewing call takeaways. Emergent Biosolutions: Q4 Earnings Snapshot
• Negative Sentiment: Q4 results missed expectations: EPS of ($0.43) vs. consensus $0.11 and revenue $148.7M vs. est. $217.5M — a clear earnings and top-line shortfall that weighed on the stock. Earnings Call Highlights: Strategic Gains Amid Revenue …
• Negative Sentiment: FY‑2026 revenue guidance was reset much lower to ~$720M–$760M versus street expectations near $1.2B; EPS guidance was not clearly reiterated in the release — the weak outlook is the primary driver of the share decline. Earnings Call Highlights: Strategic Gains Amid Revenue …

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.